drugset

drugset / Trial / NCT05030779

A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Systemic Lupus Erythematosus

NCT05030779 ↗

Phase 0 Unknown 9 enrolled Zhejiang University Yake Biotechnology Ltd. · collab

NaSingle-groupOpen-labelTreatment

Summary

A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Systemic Lupus Erythematosus

Timeline

Start: 2021-09-10
Primary completion: 2022-03-10
Completion: 2022-09-10

Publications

Feng J, Huo D, Hong R, Jin X, Cao H, Shao M, Wen R, Zhang Q, Zhang M, Fu S, Wang D, Xu H, Wei G, Cui J, Huang S, Cui D, Chang AH, Liu Z, Lu L, Lin J, Hu Y, Huang H. Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial. Nat Med. 2025 Nov;31(11):3725-3736. doi: 10.1038/s41591-025-03937-8. Epub 2025 Sep 24.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CD19/BCMA CAR T-cells	Cell therapy	1e+06 cells/kg	Intravenous
Subject	CD19/BCMA CAR T-cells	Cell therapy	4e+06 cells/kg	Intravenous

Indications